News & Media

Recent updates from Arcutis.

October 6, 2020

Arcutis Biotherapeutics Announces Closing of Public Offering and Concurrent Private Placement of Common Stock

October 1, 2020

Arcutis Biotherapeutics Announces Pricing of Public Offering and Concurrent Private Placement of Common Stock

September 29, 2020

Arcutis Biotherapeutics Announces Proposed Public Offering and Concurrent Private Placement of Common Stock

September 29, 2020

Arcutis Announces Positive Topline Data from Phase 2 Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

September 16, 2020

Arcutis Completes Enrollment in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

September 15, 2020

Arcutis to Present at the Cantor Fitzgerald Global Healthcare Conference 2020

September 8, 2020

Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast Cream) into Phase 3 Trials for the Treatment of Atopic Dermatitis Following End-of-Phase 2 Meeting with FDA

August 11, 2020

Arcutis Announces Second Quarter 2020 Financial Results and Provides Business Update

August 10, 2020

Arcutis to Present at the Wedbush PacGrow Healthcare Conference

August 4, 2020

Bethany Dudek Joins Arcutis as Vice President of Quality

August 3, 2020

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis

July 31, 2020

Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download